Genetic correlates influencing immunopathogenesis of HIV infection

Indian Journal of Medical Research

Volumn 134, Issue 12, 2011, Pages 749-768

  Sharma, Gaurav ^a   Kaur, Gurvinder ^a   Mehra, Narinder ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Chemokines; Clades; Cytokines; Exposed uninfected individuals; Genetic correlates; Genetic variants; HIV; HIV AIDS; HLA; Immunopathogenesis; Rapid and slow progressors; Viraemia controllers

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GAG PROTEIN; GAMMA INTERFERON; HLA B27 ANTIGEN; HLA B57 ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; LIGAND; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN; POL PROTEIN; RANTES; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR ALPHA; VIRUS DNA; VIRUS ENVELOPE PROTEIN; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIGEN RECOGNITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHIMPANZEE; CLADISTICS; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DRUG HYPERSENSITIVITY; ENVELOPE GENE; EPITOPE MAPPING; GENE FREQUENCY; GENE LOCUS; GENE PRODUCT; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOTYPE; HEREDITY; HETEROZYGOSITY; HIGH RISK POPULATION; HIV EXPOSED PERSISTENTLY SERONEGATIVE INDIVIDUAL; HLA SYSTEM; HOMOZYGOSITY; HOST PATHOGEN INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOGENETICS; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INFECTION CONTROL; INFECTION RATE; MACACA; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE HOMOSEXUAL; MULTIFACTORIAL INHERITANCE; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PHENOTYPE; REVIEW; RISK ASSESSMENT; RNA INTERFERENCE; SERODIAGNOSIS; SIMIAN IMMUNODEFICIENCY VIRUS; TREATMENT RESPONSE; VIREMIA; VIRION; VIROLOGY; VIRUS ENTRY; VIRUS GENOME; VIRUS LOAD; VIRUS REPLICATION;

EID: 84856568420     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: 10.4103/0971-5916.92623     Document Type: Review

References (148)

1. Belasio EF, Raimondo M, Suligoi B and Buttò S. HIV virology and pathogenetic mechanisms of infection: a brief overview. Ann Ist Super Sanità 2010; 46: 5-14.
2. Darke JW. Rates of spontaneous mutation among RNA viruses. Proc Natl Acad Sci USA 1993; 90: 4171-5.
3. Robertson DL, Sharp PM, McCutchan FE, Hahn BH. Recombination in HIV-1. Nature 1995; 374: 124-6.
4. Loussert I, Chaix M, Korber B, Letourneur F, Guures E, Allen E, et al. The variability of HIV type I group O strains isolated from Cameroonian patients living in France. J Virol 1995; 69: 5640-9.
5. Simon F, Mauclere P, Roques P, Loussert AI, Muller TMC, Saragosti S, et al. Identification of a new human immunodeficiency virus type I distinct from group M and group O. Nat Med 1998; 4: 1032-7.
6. Plantier JC, Leoz M, Dickerson JE, De Oliveira F, Cordonnier F, Lemée V, et al. A new human immunodeficiency virus derived from gorillas. Nat Med 2009; 15: 871-2.
7. Hay CM, Ruhl DJ, Basgoz NO, Wilson CC, Bilingsley JM, DePasquale MP, et al. Lack of viral escape and defective in vivo activation of human immunodeficiency virus type-1 specific cytotoxic T lymphocytes in rapidly progressive infection. J Virol 1999; 73: 5509-19.
8. Sheppard HW, Lang W, Ascher MS, Vittinghoff E, Winkelstein W. The characterization of non progressors: Long term HIV-1 infection with stable CD4 T cell levels. AIDS 1993; 7: 1159-66.
9. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, et al. Association between presence of HLA-B*5701, HLADR7, and HLA-DQ3 and hypersensitivity to HIV-1 reversetranscriptase inhibitor abacavir. Lancet 2002; 359: 727-32.
10. Rauch A, Nolan D, Thurnheer C, Fux CA, Cavassini M, Chave JP, et al. Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study. Antivir Ther 2008; 13: 1019-28.
11. Mahungu TW, Johnson MA, Owen A, Back DJ. The impact of pharmacogenetics on HIV therapy. Int J STD AIDS 2009; 20: 145-51.
12. Inagawa DT, Lee MH, Wolinsky SM, Sano K, Morales F, Kwok S, et al. Human immunodeficiency virus type 1 infection in homosexual men who remain seronegative for prolonged periods. N Engl J Med 1989; 20: 1458-62.
13. Fowke KR, Nagelkerke NJD, Kimani J, Simonsen JN, Anzala AO, Bwayo JJ, et al. Resistance to HIV-1 inat fection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet 1996; 348: 1347-51.
14. Ranki A, Mattinen S, Yorchoan R, Broder S, Ghrayeb J, Lahdevirta J, et al. T cell responses towards HIV in infected individuals with and without zidovudine therapy, and in HIVexposed sexual partners. AIDS 1989; 3: 63-9.
15. Grabar S, Selinger-Leneman H, Abgrall S, Pialoux G, Weiss L, Castagliola D. Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV. AIDS 2009; 23: 1163-9.
16. Okulicz JF, Marconi VC, Landrum ML, Wegner S, Weintrob A, Ganesan A, et al. Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. J Infect Dis 2009; 200: 1714-23.
17. Hunt PW. Natural control of HIV-1 replication and long-term nonprogression: overlapping but distinct phenotypes. J Infect Dis 2009; 200: 1636-8.
18. Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 2008; 197: 563-71.
19. Casado C, Colombo S, Rauch A, Martinez R, Gunthard HF, Garcia S, et al. Host and viral genetic correlates of clinical definitions of HIV-1 disease progression. PLoS One 2010; 5: e11079.
20. Pandrea I, Silvestri G, Apetrei C. AIDS in African nonhuman primate hosts of SIVs: A new paradigm of SIV infection. Curr HIV Res 2009; 7: 57-72.
21. Pantaleo G & Koup RA. Correlates of immune protection in HIV infection: what we know, what we don't know, what we should know. Nat Med 2004; 10: 806-10.
22. O'Brien SJ and Nelson GW. Human genes that limit AIDS. Nat Genet 2004; 36: 565-74
23. Kaur G & Mehra NK. Genetic determinants of HIV-1 infection and progression to AIDS: susceptibility to HIV infection. Tissue Ag 2009; 73: 289-301.
24. Kaur G & Mehra NK. Genetic determinants of HIV-1 infection and progression to AIDS: immune response genes. Tissue Antigens 2009; 74: 373-85.
25. Fellay J, Shianna KV, Telenti A, Goldstein B. Host Genetics and HIV-1: The Final Phase? PLoS Pathogens 2010; 6: e1001033.
26. Singh P, Kaur G, Sharma G, Mehra NK. Immunogenetic basis of HIV-1 infection, transmission and disease progression. Vaccine 2008; 26: 2966-80.
27. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, Lomb DA, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science 1997; 277: 959-65.
28. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86: 367-77.
29. Arenzana-Seisdedos F, Parmentier M. Genetics of resistance to HIV infection: Role of co-receptors and co-receptor ligands. Semin Immunol 2006; 18: 387-403.
30. Kageyama S, Mimaya J, Yamada K, Kurimura T, Shiraki K. Polymorphism of CCR5 affecting HIV disease progression in the Japanese population. AIDS Res Hum Retroviruses 2001; 17: 991-5.
31. Li M, Song R, Masiciotra S, Soriano V, Spira TJ, Lal RB, Yang C. Association of CCR5 human haplogroup E with rapid HIV type 1 disease progression. AIDS Res Hum Retroviruses 2005; 21: 111-5.
32. Lama J, Planelles V. Host factors influencing susceptibility to HIV infection and AIDS progression. Retrovirology 2007; 4: 52.
33. Gonzalez E, Kulkarni H, Bolivar H, Mangano A, Sanchez R, Catano G, et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 2005; 307: 1434-40.
34. Colobran R, Adreani P, Ashhab Y, Llano A, Este JA, Dominguez O, et al. Multiple products derived from two CCL4 loci: high incidence of a new polymorphism in HIV+ patients. J Immunol 2005; 174: 5655-64.
35. McDermott DH, Beecroft MJ, Kleeberger CA, Al-Sharif FM, Ollier WE, Zimmerman PA, et al. Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study. AIDS 2000; 14: 2671-8.
36. Heeney JL, Dalgleish AG, Weiss RA. Origins of HIV and the evolution of resistance to AIDS. Science 2006; 313: 462-6.
37. Winkler C, Modi W, Smith MW, Nelson GW, Wu X, Carrington M, et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science 1998; 279: 389-93.
38. Stephens HA. HIV-1 diversity versus HLA class I polymorphism. Trends Immunol 2005; 26: 41-7.
39. Gaudieri S, DeSantis D, McKinnon E, Moore C, Nolan D, Witt CS, et al. Killer immunoglobulin-like receptors and HLA act both independently and synergistically to modify HIV disease progression. Genes Immun 2005; 6: 683-90.
40. Lopez-Vazquez A, Mina-Blanco A, Martinez-Borra J, Njobvu PD, Suarez-Alvarez B, Blanco-Gelaz MA, et al. Interaction between KIR3DL1 and HL-B*57 supertype alleles influences the progression of HIV-1 infection in a Zambian population. Hum Immunol 2005; 66: 285-9.
41. Kang MW, Pyo CW, Wie SH, Choi HB, Kim SY, Kim YK, et al. Associations of IFN-gamma polymorphism with HIV-1 infection in the Korean population. AIDS Res Hum Retroviruses 2006; 22: 297-9.
42. Konenkov VI, Smolnikova MV. Polymorphism of promoter sites of interleukins 4 and IL10 and tumor necrosis factoralpha in HIV infected patients. Bull Exp Biol 2002; 133: 389-91.
43. Tang J, Shelton B, Makhatadze NJ, Zhang Y, Schaen M, Louie LG, et al. Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression. J Virol 2002; 76: 662-72.
44. Mehra NK, Kaur G. The HLA complex in biology and medicine. A resource book. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd. 2009.
45. Steven GE. Marsh. Nomenclature for factors of the HLA system, update September 2010, WHO.
46. Fujiwara M, Takiguchi M. HIV-1-specific CTLs effectively suppress replication of HIV-1 in HIV-1-infected macrophages. Blood 2007; 109: 4832-8.
47. Winkler CA, An P. Host genes associated with HIV/AIDS: advances in gene discovery. Trends Genet 2010; 26: 119-31.
48. Carrington M, O'Brien SJ. The influence of HLA genotype on AIDS. Annu Rev Med 2003; 54: 535-51.
49. Hulsmeyer M, Hilling RC, Volz A Ruhl M, Schroder W, Saenger W, Ziegler A. et al. HLA-B27 subtypes differentially associated with disease exhibit subtle structural alterations. J Biol Chem 2002; 277: 47844-53.
50. Gao X, Nelson GW, Karacki P, Martin MP, Phair J, Kaslow R, et al. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl J Med 2001; 344: 1668-75.
51. Gao X, Bashirova A, Iverson AK, Phair J, Goedert JJ, Buchbinder S, et al. AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis. Nat Med 2005; 11: 1290-2.
52. The allele frequency net database for frequency distribution of alleles in various populations, Available from: www. allelefrequencies.net, accessed on June, 2011.
53. Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert JJ, et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 1999; 283: 1748-52.
54. Flores Villanueva PO, Yunis EJ, Delgado JC, Vittinghoff E, Buchbinder S, Leung JY, et al. Control of HIV viremia and protection from AIDS are associated with HLA-Bw4 homozygosity. Proc Natl Acad Sci USA 2001; 98: 5140-5.
55. Sette A, Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and-B polymorphism. Immunogenetics 1999; 50: 201-12.
56. MacDonald KS, Embree JE, Nagelkerke NJ, Castillo J, Ramhadin S, Njenga S, et al. The HLA A2/6802 supertype is associated with reduced risk of perinatal human immunodeficiency virus type 1 transmission. J Infect Dis 2001; 183: 503-6.
57. Liu C, Carrington M, Kaslow RA, Richard A, Gao X, Charles R, et al. Association of polymorphisms in human leukocyte antigen class I and transporter associated with antigen processing genes with resistance to human immunodeficiency virus type 1 infection. J Infect Dis 2003; 187: 1404-10.
58. Kaslow RA, Carrington M, Apple R, Park L, Munoz A, Saah AI, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996; 2: 405-11.
59. Dorak MT, Tang J, Tang S, Penman-Aquilar A, Cutinho RA, Goedert JJ, et al. Influence of human leukocyte antigen-B22 alleles on the course of human immunodeficiency virus type 1 infection in 3 cohorts of white men. J Infect Dis 2003; 188: 856-63.
60. Flores-Villanueva PO, Hendel H, Caillat-Zucman S, Rappaport J, Burgos-Tiburcia A, Bertin Maghit S, et al. Associations of MHC ancestral haplotypes with resistance/susceptibility to AIDS disease development. J Immunology 2003; 170: 1925-9.
61. Vyakarnam A, Sidebottom D, Murad S, Underhill JA, Easterbrook PJ, Dalgleish AG, et al. Possession of human leucocyte antigen DQ6 alleles and the rate of CD4 T-cell decline in human immunodeficiency virus-1 infection. Immunology 2004; 112: 136-42.
62. Li S, Jiao H, Yu X, Strong AJ, Shao Y, Sun Y, et al. Human leukocyte antigen class I and class II allele frequencies and HIV-1 infection associations in a Chinese cohort. J Acquir Immune Defic Syndr 2007; 44: 121-31.
63. Dorak MT, Yee LJ, Tang J, Shao W, Lobasheusky ES, Jacobson LP, Kaslow RA. HLA-B,-DRB1/3/4/5, and-DQB1 gene polymorphisms in human immunodeficiency virus-related Kaposi's sarcoma. J Med Virol 2005; 76: 302-10.
64. Louie LG, Hartogensis WE, Jackman RP, Schultz KA, Zijenah LS, Yiu CHY, et al. Mycobacterium tuberculosis/HIV-1 coinfection and disease: role of human leukocyte antigen variation. J Infect Dis 2004; 189: 1084-90.
65. Winchester R, Chen Y, Rose S, Selby J, Borkowsky W. Major histocompatibility complex class II DR alleles DRB1*1501 and those encoding HLA-DR13 are preferentially associated with a diminution in maternally transmitted human immunodeficiency virus 1 infection in different ethnic groups: determination by an automated sequence-based typing method. Proc Natl Acad Sci USA 1995; 92: 12374-8.
66. Selvaraj P, Swaminathan S, Alagarasu K, Raghavan S, Narendran G, Narayanan, P. Association of human leukocyte antigen-A11 with resistance and B40 and DR2 with susceptibility to HIV-1 infection in south India. J Acquir Immune Defic Syndr 2006; 43: 497-9.
67. Steel CM, Ludlam CA, Beatson D, Peutherer JF, Cuthbert RJG, Simmonds P, et al. HLA haplotype A1, B8, DR3 as a risk factors for HIV related disease. Lancet 1988; 1: 1185-8.
68. Price P, Witt C, Allcock R, Sayer D, Garlepp M, Kok CC, et al. The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunol Rev 1999; 167: 257-74.
69. Witt CS, Price P, Kaur G, Mehra NK, Cheong K, Kanga U, et al. Common HLA-B8-DR3 haplotype in Northern India is different from that found in Europe. Tissue Agents 2002; 60: 474-80.
70. Kaur G, Sarkar N, Bhatnagar S, Kumar S, Rapthap CC, Bhan MK, et al. Pediatric celiac disease in India is associated with multiple DR3-DQ2 haplotypes. Hum Immunol 2002; 63: 677-82.
71. Kanga U, Vaidyanathan B, Jaini R, Menon PS, Mehra NK. HLA haplotypes associated with type 1 diabetes mellitus in North Indian children. Hum Immunol 2004; 65: 47-53.
72. Shankarkumar U, Thakar M, Mehendale S, Praranjape RS, Mohanty D. Association of HLA B*3520, B*1801, and Cw*1507 with HIV-1 infection Maharashtra, India. J Acquir Immune Defic Syndr 2003; 34: 113-4.
73. Aberg JA, Kaplan JE LH, Emmanual P, Anderson JR, Stone VE, Oleske JM. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2009; 49: 651-81.
74. Chessman D, Kostenko L, Lethborg T, Purcell AW, Williamson NA, Chen Z, et al. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 2008; 28: 822-32.
75. Rousseau CM, Lockhart DW, Listgarten J, Maley SN, Kadie C, Learn GH, et al. Rare HLA drive additional HIV evolution compared to more frequent alleles. AIDS Res Hum Retroviruses 2009; 25: 297-303.
76. Kawashima Y, Pfafferott K, Frater J, Matthews P, Payne R, Addo M, et al. Adaptation of HIV-1 to human leukocyte antigen class I. Nature 2009; 458: 641-5.
77. Luster AD. Chemokines: chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 388: 436-45.
78. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, et al. Identification of a major coreceptor for primary isolates of HIV-1. Nature 1996; 381: 661-6.
79. Cocchi F, De Vico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1α and MIP-1β as the major HIV suppressive factors produced by CD8+ T cells. Science 1995; 270: 1811-5.
80. Lusso P. HIV and the chemokine system: 10 year later. EMBO J 2006; 25: 447-56.
81. Kostrikis LG, Huang Y, Moore JP, Wolinsky SM, Zhang L, Guo Y, et al. A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat Med 1998; 4: 350-3.
82. Louisirirotchanakul S, Liu H, Roongpisuthipong A, Nakayama EE, Takebe Y, Shioda T, et al. Genetic analysis of HIV-1 discordant couples in Thailand: association of CCR2 64I homozygosity with HIV-1-negative status. J Acquir Immune Defic Syndr 2002; 29: 314-5.
83. Zhang XL, Zhang CY, Yu Y, Chen F, Li P, Fu SB. CCR2 allele polymorphisms in 15 Chinese ethnic populations. Int J Immunogenet 2006; 33: 45-8.
84. Gonzalez E, Bamshad M, Sato N, Mummidi S, Dhanda R, Catano G, Cabrera S. Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes. Proc Natl Acad Sci USA 1999; 96: 12004-9.
85. Kaur G, Singh P, Kumar N, Rapthap CC, Sharma G, Vajpayee M, et al. Distribution of CCR2 polymorphism in HIV-1-infected and healthy subjects in North India. Int J Immunogenet 2007; 34: 153-6.
86. Suresh P, Wanchu A, Sachdeva RK, Bhatnagar A. Gene polymorphisms in CCR5, CCR2, CX3CR1, SDF-1 and RANTES in exposed but uninfected partners of HIV-1 infected individuals in North India. J Clin Immunol 2006; 26: 476-84.
87. Martinson JJ, Chapman NH, Rees DC, Liu YT, Clegg JB. Global distribution of the CCR5 gene 32-basepair deletion. Nat Genet 1997; 16: 100-3.
88. Kaur G, Singh P, Rapthap CC, Kumar N, Vajpayee M, Sharma SK, et al. Polymorphism in the CCR5 gene promoter and HIV-1 infection in North Indians. Hum Immunol 2007; 68: 454-61.
89. Husain S, Goila R, Shahi S, Banerjea A. First report of a healthy Indian heterozygous for delta 32 mutant of HIV-1 coreceptor-CCR5 gene. Gene 1998; 207: 141-7.
90. Majumder PP, Dey B. Absence of the HIV-1 protective Delta ccr5 allele in most ethnic populations of India. Eur J Hum Genet 2001; 9: 794-6.
91. Verma R, Gupta RB, Singh K, Bhasin R, Shukla AA, Chauhan SS, et al. Distribution of CCR5delta32, CCR2-64I and SDF1-3'A and plasma levels of SDF-1 in HIV-1 seronegative North Indians. J Clin Virol 2007; 38: 198-203.
92. McDermott DH, Zimmerman PA, Guignard F, Kleeberger CA, Leitman SF, Murphy PM. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet 1998; 352: 866-70.
93. Kostrikis LG, Neumann AU, Thomson B, Korber BT, McHardy P, Karanicolas R, et al. A polymorphism in the regulatory region of the CC-chemokine receptor 5 gene influences perinatal transmission of human immunodeficiency virus type 1 to African-American infants. J Virol 1999; 73: 10264-71.
94. Nguyen L, Li M, Chaowanachan T, Hu DJ, Vanichseni S, Mock PA, et al. CCR5 promoter human haplogroups associated with HIV-1 disease progression in Thai injection drug users. AIDS 2004; 18: 1327-33.
95. Sriwanthana B, Hodge T, Mastro, TD, Dezzutti CS, Bond K, Stephens HA, et al. HIV-specific cytotoxic T lymphocytes, HLA-A11, and chemokine-related factors may act synergistically to determine HIV resistance in CCR5 delta32-negative female sex workers in Chiang Rai, northern Thailand. AIDS Res Hum Retroviruses 2001; 17: 719-34.
96. Martin MP, Dean M, Smith MW, Winkler C, Gerrard B, Michael NL, et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 1998; 282: 1907-11.
97. Menten P, Wuyts A, Van Damme J. Macrophage inflammatory protein-1. Cytokine Growth Factor Rev 2002; 13: 455-81.
98. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interfer Cytok Res 2009; 29: 313-26.
99. Weiss JM, Nath A, Major EO and Berman JW. HIV-1 Tat Induces Monocyte Chemoattractant Protein-1-Mediated Monocyte Transmigration Across a Model of the Human Blood-Brain Barrier and Up-Regulates CCR5 Expression on Human Monocytes. J Immunol 1999; 163: 2953-9.
100. Rovin B, Lu L, Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biophy Biochem Res Commun 1999; 259: 344-8.
101. Gonzalez E, Rovin BH, Sen L, Cooke G, Dhanda R, Mummidi S, et al. HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infilteration of tissues and MCP-1 levels. Proc Nat Acad Sci USA 2002; 99: 13795-800.
102. Cam FS, Sekuri C, Segcan A, Ercan E, Tengiz I, Alioglu E, Berdeli A, et al. Effect of Monocyte chemoattractant protein 1 (MCP-1) gene polymorphism in Turkish patients with premature coronary artery disease. Scand J Immunogenet 2008; 68: 801-5.
103. Hwang SY, Cho ML, Park B, Kim JY, Kim YH, Min DJ, et al. Allelic frequency of the Monocyte chemoattractant protein 1 (MCP-1) promoter-2518 polymorphism in the Korean population and in Korean patients with rheumatoid arthritis, systemic lupus erythematosus and adult onset Still's disease. Eur J Immunogen 2002; 29: 413-6.
104. Alagarasu K, Selvaraj P, Swaminathan S, Raghvan S, Narendran G, Narayanan PR, et al. CCR2, MCP-1, SDF-1 alpha and DC-SIGN gene polymorphisms in HIV-1 infected patients with and without TB. Indian J Med Res 2009; 130: 444-50.
105. Brambilla A, Villa C, Rizzardi G, Veglia F, Ghezzi S, Lazzarin A, et al. Shorter survival of SDF1-3'A/3'A homozygotes linked to CD4+ T cell decrease in advanced human immunodeficiency virus type 1 infection. J Infect Dis 2000; 182: 311-5.
106. Vidal F, Peraire J, Domingo P, Broch M, Knobel H, Pedrol E, et al. Chemokines and Long-Term Nonprogressor Study Group. Lack of association of SDF-1 3A variant allele with long-term nonprogressive HIV-1 infection is extended beyond 16 years. J Acquir Immune Defic Syndr 2005; 40: 276-9.
107. John GC, Rousseau C, Dong T, Jones SR, Nduati R, Nagacha DM, et al. Maternal SDF1 3′A polymorphism is associated with increased perinatal human immunodeficiency virus type 1 transmission. J Virol 2000; 74: 5736-9.
108. Tiensiwakul P. Stromal cell derived factor (SDF)1-3'A polymorphism may play a role in resistance to HIV-1 infection in seronegative high risk Thais. Intervirology 2004; 47: 87-92.
109. Ramana GV, Vasanthi A, Khaja M, Su B, Govindaiah V, Jin L, et al. Distribution of HIV-1 resistance conferring polymorphic alleles SDF1-3'A, CCR2-64I and CCR5del32 in diverse populations of Andhra Pradesh, South India. J Genet 2001; 80: 137-40.
110. Su B, Sun G, Lu D, Xiao J, Hu F, Chakraborty R, et al. Distribution of three HIV-1 resistance conferring polymorphisms (SDF1-3'A, CCR2-64I and CCR5-delta32) in global populations. Eur J Hum Genet 2000; 8: 975-9.
111. Gallo RC, Garzino-Demo A, DeVico AL. HIV infection and pathogenesis: what about chemokines? J Clin Immunol 1999; 19: 293-9.
112. Liu H, Chao D, Nakayama EE, Taguchi H, Goto M, Xin X, et al. Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci USA 1999; 96: 4581-5.
113. Nickel RG, Casolaro V, Wahn U, Beyer K, Barnes KC, Plunkett BS, et al. Atopic dermatitis is associated with a functional mutation in the promoter of the C-C chemokine RANTES. J Immunol 2000; 164: 1612-6.
114. Wichukchinda N, Nakayama EE, Rojanawiwat A, Pathipvanich P, Auwanit W, Vongsheree S, et al. Protective effects of IL4-589T and RANTES-28G on HIV-1 disease progression in infected Thai females. AIDS 2006; 20: 189-96.
115. Zhao XY, Lee SS, Wong KH, Chan KC, Ma S, Yam WC, et al. Effects of single nucleotide polymorphisms in the RANTES promoter region in healthy and HIV-infected indigenous Chinese. Eur J Immunogenet 2004; 31: 179-83.
116. Gonzalez E, Dhanda R, Bamshad M, Mummidi S, Geevarghese R, Catano G, et al. Global survey of genetic variability in CCR5, RANTES and MIP-1 alpha: Impact on the epidemiology of the HIV-1 pandemic. Proc Nat Acad Sci USA 2001; 98: 5199-204.
117. Dolan MJ, Kulkarni H, Camargo JF, He W, Smith A, Anaya JM, et al. CCL3L1 and CCR5 influence cell mediated immunity and affect HIV-AIDS pathogenesis via viral entryindependent mechanisms. Nat Immunol 2007; 8: 1324-36.
118. Nakajima T, Kaur G, Mehra NK, Kimura A. HIV-1/AIDS susceptibility and copy number variation in CCL3L1, a gene encoding a natural ligand for HIV-1 co-receptor CCR5. Cytogenet Genome Res 2008; 123: 156-60.
119. Ahuja SK, Kulkarni H, Catano G, Agan BK, Camargo JF, et al. CCL3L1-CCR5 genotype influences durability of immune recovery during anti retro viral therapy of HIV-1 infected individuals. Nat Med 2008; 14: 413-20.
120. Kulkarni H, Agan BK, Marconi VC, O'Connell RJ, Camargo JF, He W, et al. CCL3L1-CCR5 genotypes improves the assessment of AIDS risk in HIV-1 infected individuals. PLoS One 2008; 3: e3165.
121. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effect of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997; 94: 3195-9.
122. Hutchinson IV, Pravica V, Perrey C, Sinnott P. Cytokine gene polymorphisms and relevance to forms of rejection. Transpl Proc 1999; 31: 734-6.
123. Imami N, Pires A, Hardy G, Wilson J, Gazzard B, Gotch F. A balanced type 1/type 2 response is associated with longterm nonprogressive human immunodeficiency virus type 1 infection. J Virol 2002; 76: 9011-23.
124. Shin HD, Winkler C, Stephens JC, Bream J, Young H, Goedert JJ, et al. Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci USA 2000; 97: 14467-72.
125. Vasilescu A, Heath SC, Ivanova R, Hendel H, Do H, Mazoyer A, et al. Genomic analysis of Th1-Th2 cytokine genes in an AIDS cohort: identification of IL4 and IL10 haplotypes associated with the disease progression. Genes Immun 2003; 4: 441-9.
126. Soriano A, Lozano F, Oliva H, Garcia F, Nomdedeu M, De Lazzari E, et al. Polymorphisms in the interleukin-4 receptor alpha chain gene influence susceptibility to HIV-1 infection and its progression to AIDS. Immunogenetics 2005; 57: 644-54.
127. Osborn L, Kunkel S, Nabel GJ. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc Natl Acad Sci USA 1989; 86: 2336-40.
128. Price P, James I, Fernandez S, French MA. Alleles of the gene encoding IL-1 alpha may predict control of plasma viremia in HIV-1 patients on highly active antiretroviral therapy. AIDS 2004; 18: 1495-501.
129. Vicenzi E, Biswas P, Mengozzi M, Poli G. Role of proinflammatory cytokines and beta-chemokines in controlling HIV replication. J Leukoc Biol 1997; 62: 34-40.
130. Billiau A, Heremans H, Vermeire K, Matthys P. Immunomodulatory properties of interferon-gamma. An update. Ann N Y Acad Sci 1998; 856: 22-32.
131. Pravica V, Asderakis A, Perrey C, Hajeer A, Sinnott PJ, Hutchinson IV. In vitro production of IFN-gamma correlates with CA repeat polymorphism in the human IFN-gamma gene. Eur J Immunogenet 1999; 26: 1-3.
132. Jacob CO, Fronek Z, Lewis GD, Koo M, Hansen JA, McDevitt HO. Heritable major histocompatibility complex class IIassociated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci USA 1990; 87: 1233-7.
133. Abraham LJ, French MA, Dawkins RL. Polymorphic MHC ancestral haplotypes affect the activity of tumour necrosis factor-alpha. Clin Exp Immunol 1993; 92: 14-8.
134. Brinkman BM, Keet IP, Miedema F, Verweij CL, Klein MR. Polymorphisms within the human tumor necrosis factor-alpha promoter region in human immunodeficiency virus type 1-seropositive persons. J Infect Dis 1997; 175: 188-90.
135. Valentin A, Lu W, Rosati M, Schneider R, Albert J, Karlsson A, et al. Dual effect of interleukin-4 on HIV-1 expression: implications for phenotypic switch and disease progression. Proc Natl Acad Sci USA 1998; 95: 8886-91.
136. Vidyarani M, Selvaraj P, Prabhu Anand S, Jawahar MS, Adhilakshmi AR, et al. Interferon gamma (IFNgamma) & interleukin-4 (IL-4) gene variants & cytokine levels in pulmonary tuberculosis. Indian J Med Res 2006; 124: 403-10.
137. Leigh JK, The study of polymorphism in cytokine and cytokine receptor genes Scientific communications. ASHI Q 2002; 152-76.
138. Kaur G, Rapthap CC, Kumar N, Kumar S, Neolia S, Mehra NK. Frequency distribution of cytokine gene polymorphisms in the healthy North Indian population. Tissue Antigens 2007; 69:113-20.
139. Hoffmann SC, Stanley EM, Cox ED, Di Mercurio BS, Koziol DE, Harlan DM, et al. Ethnicity greatly influences cytokine gene polymorphism distribution. Am J Transplant 2002; 2: 560-7.
140. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007; 317: 944-7.
141. Dalmasso C, Carpentier W, Meyer L, Rouzioux C, Goujard C, Chaix ML, et al. Distinct genetic loci control plasma HIVRNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study. PloS One 2008; 3: e3907.
142. Le Clerc S, Limou S, Coulonges C, Carpentier W, Dina C, Taing L, et al. Genomewide association study of a rapid progression cohort identifies new susceptibility alleles for AIDS (ANRS Genomewide Association Study 03). J Infect Dis 2009; 200: 1194-201.
143. Limou S, Le Clerc S, Coulonges C, Carpentier W, Dina C, Delaneau O, et al. Genomewide association study of an AIDS nonprogression cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 02). J Infect Dis 2009; 199: 419-26.
144. Loeuillet, C, Deutsch S, Ciuffi A, Robyr D, Taffe P, Munoz M, et al. In vitro whole-genome analysis identifies a susceptibility locus for HIV-1. PLoS Biol 2008; 6: e32
145. Brass AL, Dykxhoorn DM, Benita Y, Yan N, Engelman A, Xavier RJ, et al. Identification of host proteins required for HIV infection through a functional genomic screen. Science 2008; 319: 921-6.
146. Zhou H, Xu M, Huang Q, Gates AT, Zhang XD, Castle JC, et al. Genome-scale RNAi screen for host factors required for HIV replication. Cell Host Microbe 2008; 4: 495-504.
147. Konig R, Zhou Y, Elleder D, Diamond TL, Bonamy GMC, Irelan JT, et al. Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell 2008; 135: 49-60.
148. Yeung ML, Houzet L, Yedavalli VS, Jeang KT. A genomewide short hairpin RNA screening of jurkat T-cells for human proteins contributing to productive HIV-1replication. J Biol Chem 2009; 284: 19463-73.